{"id":73815,"date":"2026-04-20T11:13:07","date_gmt":"2026-04-20T05:43:07","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=73815"},"modified":"2026-04-20T11:13:09","modified_gmt":"2026-04-20T05:43:09","slug":"paushak-q4-results-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/paushak-q4-results-2026\/","title":{"rendered":"Paushak Q4 Results 2026: Date, Revenue, PAT &#038; Analyst Outlook"},"content":{"rendered":"<p>Paushak (NSE: PAUSHAK) is preparing to announce its Q4 FY26 financial results for the quarter ended March 31, 2026. With Paushak trading at Rs 4,200 \u2014 against a 52-week high of Rs 6,800 and a 1-year return of -32% \u2014 the Q4 FY26 results will be a pivotal event for investors tracking the Specialty Chemicals sector.<\/p><p>Analyst estimates for Q4 FY26 revenue stand at Rs 88\u2013102 Cr, with PAT expectations of Rs 18\u201326 Cr and margin projections of EBITDA 25\u201332%. This article covers the Paushak Q4 results 2026 date, detailed earnings estimates, five key performance factors, five risks to monitor, analyst ratings, and answers to the most commonly searched investor questions.<\/p><p>Get free investment predictions on <a href=\"https:\/\/univest.in\/user\/log-in\">Univest<\/a>.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/paushak-q4-results-2026\/#Paushak_Q4_Results_2026_Date\" title=\"Paushak Q4 Results 2026 Date\">Paushak Q4 Results 2026 Date<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/paushak-q4-results-2026\/#Why_This_Quarter_Matters\" title=\"Why This Quarter Matters\">Why This Quarter Matters<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/paushak-q4-results-2026\/#Paushak_Q4_FY26_Earnings_Estimates\" title=\"Paushak Q4 FY26 Earnings Estimates\">Paushak Q4 FY26 Earnings Estimates<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/paushak-q4-results-2026\/#5_Key_Factors_That_Will_Drive_Paushak_Q4_FY26_Performance\" title=\"5 Key Factors That Will Drive Paushak Q4 FY26 Performance\">5 Key Factors That Will Drive Paushak Q4 FY26 Performance<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/paushak-q4-results-2026\/#Phosgene_Chemistry_Monopoly\" title=\"Phosgene Chemistry Monopoly\">Phosgene Chemistry Monopoly<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/paushak-q4-results-2026\/#CDMO_and_Pharma_Intermediate_Exports\" title=\"CDMO and Pharma Intermediate Exports\">CDMO and Pharma Intermediate Exports<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/paushak-q4-results-2026\/#Margin_Sustainability_at_25%E2%80%9332\" title=\"Margin Sustainability at 25\u201332%\">Margin Sustainability at 25\u201332%<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/paushak-q4-results-2026\/#Capacity_Expansion_and_Revenue_Scalability\" title=\"Capacity Expansion and Revenue Scalability\">Capacity Expansion and Revenue Scalability<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/paushak-q4-results-2026\/#Ahmedabad_Site_Safety_and_Regulatory_Compliance\" title=\"Ahmedabad Site Safety and Regulatory Compliance\">Ahmedabad Site Safety and Regulatory Compliance<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/paushak-q4-results-2026\/#5_Risks_to_Watch_in_Paushak_Q4_FY26\" title=\"5 Risks to Watch in Paushak Q4 FY26\">5 Risks to Watch in Paushak Q4 FY26<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/paushak-q4-results-2026\/#Single-Product_Concentration\" title=\"Single-Product Concentration\">Single-Product Concentration<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/paushak-q4-results-2026\/#Hazardous_Process_Risk\" title=\"Hazardous Process Risk\">Hazardous Process Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/paushak-q4-results-2026\/#Customer_Concentration_in_Pharma\" title=\"Customer Concentration in Pharma\">Customer Concentration in Pharma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/paushak-q4-results-2026\/#Regulatory_Approval_Risk\" title=\"Regulatory Approval Risk\">Regulatory Approval Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/paushak-q4-results-2026\/#Premium_Valuation_Vulnerability\" title=\"Premium Valuation Vulnerability\">Premium Valuation Vulnerability<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/paushak-q4-results-2026\/#Paushak_Share_Price_and_Analyst_Ratings\" title=\"Paushak Share Price and Analyst Ratings\">Paushak Share Price and Analyst Ratings<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/paushak-q4-results-2026\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/paushak-q4-results-2026\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/paushak-q4-results-2026\/#What_is_the_Paushak_Q4_results_2026_date\" title=\"What is the Paushak Q4 results 2026 date?\">What is the Paushak Q4 results 2026 date?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/paushak-q4-results-2026\/#What_is_the_Paushak_Q4_FY26_PAT_estimate\" title=\"What is the Paushak Q4 FY26 PAT estimate?\">What is the Paushak Q4 FY26 PAT estimate?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/paushak-q4-results-2026\/#What_is_Paushaks_share_price_ahead_of_Q4_results\" title=\"What is Paushak&#8217;s share price ahead of Q4 results?\">What is Paushak&#8217;s share price ahead of Q4 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/paushak-q4-results-2026\/#Will_Paushak_declare_a_dividend_in_Q4_2026\" title=\"Will Paushak declare a dividend in Q4 2026?\">Will Paushak declare a dividend in Q4 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/paushak-q4-results-2026\/#Which_analysts_have_a_Buy_rating_on_Paushak\" title=\"Which analysts have a Buy rating on Paushak?\">Which analysts have a Buy rating on Paushak?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/paushak-q4-results-2026\/#What_were_Paushak_Q3_FY26_results\" title=\"What were Paushak Q3 FY26 results?\">What were Paushak Q3 FY26 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/paushak-q4-results-2026\/#When_do_Infosys_and_TCS_announce_Q4_results_2026\" title=\"When do Infosys and TCS announce Q4 results 2026?\">When do Infosys and TCS announce Q4 results 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/paushak-q4-results-2026\/#Is_Paushak_a_good_investment_ahead_of_Q4_results\" title=\"Is Paushak a good investment ahead of Q4 results?\">Is Paushak a good investment ahead of Q4 results?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/paushak-q4-results-2026\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Paushak_Q4_Results_2026_Date\"><\/span><strong>Paushak Q4 Results 2026 Date<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Company<\/strong><\/td><td><strong>Q4 FY26 Results Date<\/strong><\/td><td><strong>Sector<\/strong><\/td><\/tr><tr><td><a href=\"https:\/\/univest.in\/blogs\/tcs-q4-results-2026-date-preview\">TCS<\/a><\/td><td>April 9, 2026<\/td><td>IT Services<\/td><\/tr><tr><td><a href=\"https:\/\/univest.in\/blogs\/infosys-q4-results-2026-date-preview\">Infosys<\/a><\/td><td>April 23, 2026<\/td><td>IT Services<\/td><\/tr><tr><td>Paushak<\/td><td>May 2026 (Expected)<\/td><td>See article<\/td><\/tr><\/tbody><\/table><\/figure><p>Paushak has scheduled its Q4 FY26 results for May 2026 (Expected). The board of directors will meet to approve audited financial statements for the quarter ended March 31, 2026, and to consider a final dividend recommendation. At a CMP of Rs 4,200, investors will closely watch this announcement for revenue growth confirmation and FY27 guidance.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Why_This_Quarter_Matters\"><\/span><strong>Why This Quarter Matters<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Q4 FY26 is the final quarter of the financial year \u2014 it determines full-year FY26 performance, sets the FY27 estimate base, and triggers final dividend announcements. For Paushak, operating in the Specialty Chemicals sector, Q4 will reveal whether earlier-quarter momentum has sustained and whether management&#8217;s strategic initiatives are delivering measurable financial outcomes.<\/p><p>At a 1-year return of -32%, the Q4 FY26 results and FY27 guidance commentary will be critical in determining whether the stock can recover toward its 52-week high of Rs 6,800. Investors will focus on order book updates, margin trajectory, and management tone \u2014 positive surprises on multiple parameters could drive a meaningful re-rating.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Paushak_Q4_FY26_Earnings_Estimates\"><\/span><strong>Paushak Q4 FY26 Earnings Estimates<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-large\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"536\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20111020\/Paushak-Q4-FY26-Analyst-Estimates-at-a-Glance-Source-MOFSL-YES-Securities-JM-Financial-1024x536.jpg\" alt=\"Paushak Q4 FY26 Analyst Estimates at a Glance  Source MOFSL, YES Securities, JM Financial\" class=\"wp-image-73820\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20111020\/Paushak-Q4-FY26-Analyst-Estimates-at-a-Glance-Source-MOFSL-YES-Securities-JM-Financial-1024x536.jpg 1024w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20111020\/Paushak-Q4-FY26-Analyst-Estimates-at-a-Glance-Source-MOFSL-YES-Securities-JM-Financial-300x157.jpg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20111020\/Paushak-Q4-FY26-Analyst-Estimates-at-a-Glance-Source-MOFSL-YES-Securities-JM-Financial-768x402.jpg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20111020\/Paushak-Q4-FY26-Analyst-Estimates-at-a-Glance-Source-MOFSL-YES-Securities-JM-Financial-900x471.jpg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20111020\/Paushak-Q4-FY26-Analyst-Estimates-at-a-Glance-Source-MOFSL-YES-Securities-JM-Financial-600x314.jpg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20111020\/Paushak-Q4-FY26-Analyst-Estimates-at-a-Glance-Source-MOFSL-YES-Securities-JM-Financial-150x79.jpg 150w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20111020\/Paushak-Q4-FY26-Analyst-Estimates-at-a-Glance-Source-MOFSL-YES-Securities-JM-Financial.jpg 1200w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure><p>Access premium SEBI-registered research on <a href=\"https:\/\/univest.in\/user\/log-in\">Univest<\/a>.<\/p><p>Analysts covering Paushak have published Q4 FY26 estimates reflecting sector trends and company-specific catalysts. Consensus points to revenue of Rs 88\u2013102 Cr, PAT of Rs 18\u201326 Cr, and margins of EBITDA 25\u201332%. These projections incorporate Q4 seasonal strength and ongoing business improvements.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Metric<\/strong><\/td><td><strong>Q3 FY26 Actual<\/strong><\/td><td><strong>Q4 FY26 Estimate<\/strong><\/td><\/tr><tr><td>Revenue<\/td><td>Rs 78 Cr<\/td><td>Rs 88\u2013102 Cr<\/td><\/tr><tr><td>PAT<\/td><td>Rs 15 Cr<\/td><td>Rs 18\u201326 Cr<\/td><\/tr><tr><td>Margin<\/td><td>EBITDA 27.5%<\/td><td>EBITDA 25\u201332%<\/td><\/tr><tr><td>Growth Driver<\/td><td>Base quarter<\/td><td>Recovery catalyst<\/td><\/tr><tr><td>Dividend<\/td><td>Rs 50 per share<\/td><td>Rs 25\u201340 per share<\/td><\/tr><\/tbody><\/table><\/figure><p>Beyond headline numbers, investors should monitor FY27 guidance commentary, working capital trends, and order book visibility. A clean recurring profit print \u2014 rather than one inflated by non-operational items \u2014 carries greater weight with long-term investors.<\/p><p>Screen <a href=\"https:\/\/univest.in\/screeners\">Paushak<\/a> fundamentals on <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Key_Factors_That_Will_Drive_Paushak_Q4_FY26_Performance\"><\/span><strong>5 Key Factors That Will Drive Paushak Q4 FY26 Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Phosgene_Chemistry_Monopoly\"><\/span><strong>Phosgene Chemistry Monopoly<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Paushak is one of very few companies in India licensed to handle phosgene \u2014 an extremely hazardous industrial gas used in pharmaceutical synthesis. This creates a near-monopoly moat for the company in India&#8217;s phosgene-based specialty chemical market. Q4 FY26 revenue growth reflects the growing demand from domestic and global pharma clients for phosgene-derived intermediates.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"CDMO_and_Pharma_Intermediate_Exports\"><\/span><strong>CDMO and Pharma Intermediate Exports<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Paushak&#8217;s customer base includes leading global pharmaceutical companies sourcing complex phosgene-based intermediates for drug synthesis. Q4 FY26 export revenue \u2014 representing 55\u201360% of total revenues \u2014 will reflect the health of global pharma CDMO demand. Any new long-term supply agreement with a global pharma company would be a significant re-rating catalyst.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Margin_Sustainability_at_25%E2%80%9332\"><\/span><strong>Margin Sustainability at 25\u201332%<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Paushak&#8217;s high EBITDA margins \u2014 among the highest in Indian specialty chemicals \u2014 reflect the combination of hazardous chemistry expertise, limited competition, and premium pricing power. Q4 FY26 will test whether these margins can be sustained despite input cost pressures and any customer renegotiations.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Capacity_Expansion_and_Revenue_Scalability\"><\/span><strong>Capacity Expansion and Revenue Scalability<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Paushak has been investing in capacity additions to meet growing pharma intermediate demand. Q4 FY26 will reflect the initial revenue contribution from newly commissioned capacity. Management commentary on timeline to full utilisation of new capacity will inform FY27 revenue estimates.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Ahmedabad_Site_Safety_and_Regulatory_Compliance\"><\/span><strong>Ahmedabad Site Safety and Regulatory Compliance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Paushak&#8217;s Vadodara manufacturing facility operates under strict safety and environmental regulations given the hazardous nature of phosgene chemistry. Any safety incident or regulatory compliance issue would immediately halt operations and materially impact revenue. Q4 FY26 safety record will be an important operational indicator.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Risks_to_Watch_in_Paushak_Q4_FY26\"><\/span><strong>5 Risks to Watch in Paushak Q4 FY26<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Single-Product_Concentration\"><\/span><strong>Single-Product Concentration<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Paushak&#8217;s revenues are highly concentrated in phosgene-based chemistry. While the moat is strong, a technological disruption that enables pharma companies to bypass phosgene chemistry would structurally threaten the business.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Hazardous_Process_Risk\"><\/span><strong>Hazardous Process Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Phosgene is one of the most dangerous industrial chemicals. Any accident at Paushak&#8217;s plant would halt operations, create regulatory scrutiny, and generate significant liability \u2014 both financial and reputational.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Customer_Concentration_in_Pharma\"><\/span><strong>Customer Concentration in Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Paushak&#8217;s revenues are concentrated in a few large global pharma customers. Loss of a key customer \u2014 due to competitive sourcing or supply chain restructuring \u2014 would materially impact revenues.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Regulatory_Approval_Risk\"><\/span><strong>Regulatory Approval Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Paushak&#8217;s products are used in pharma manufacturing subject to stringent regulatory approvals. Any GMP compliance issue or import alert from US FDA or EU EMA would disrupt supply to regulated market customers.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Premium_Valuation_Vulnerability\"><\/span><strong>Premium Valuation Vulnerability<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Paushak trades at a significant premium to specialty chemical peers based on its unique business model. Any earnings disappointment \u2014 even a temporary one \u2014 could trigger disproportionate valuation compression given the premium multiple.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Paushak_Share_Price_and_Analyst_Ratings\"><\/span><strong>Paushak Share Price and Analyst Ratings<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-full\"><img decoding=\"async\" width=\"931\" height=\"486\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20110849\/image-1135.jpeg\" alt=\"Paushak Share Price &amp; Analyst Ratings | Source: NSE\/BSE, Broker Notes\" class=\"wp-image-73818\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20110849\/image-1135.jpeg 931w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20110849\/image-1135-300x157.jpeg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20110849\/image-1135-768x401.jpeg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20110849\/image-1135-900x470.jpeg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20110849\/image-1135-600x313.jpeg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20110849\/image-1135-150x78.jpeg 150w\" sizes=\"(max-width: 931px) 100vw, 931px\" \/><\/figure><p>Paushak is trading at Rs 4,200 as of early April 2026, against a 52-week high of Rs 6,800 and 52-week low of Rs 3,500. Market cap stands at Rs 1,850 Cr. The 1-year return of -32% reflects sector headwinds alongside company-specific factors. Analyst price targets range from the conservative to the optimistic, reflecting differing views on recovery pace and FY27 earnings potential.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Brokerage<\/strong><\/td><td><strong>Rating<\/strong><\/td><td><strong>Target Price<\/strong><\/td><td><strong>Thesis<\/strong><\/td><\/tr><tr><td>MOFSL<\/td><td>Buy<\/td><td>Rs 5,500<\/td><td>Phosgene chemistry moat<\/td><\/tr><tr><td>YES Securities<\/td><td>Buy<\/td><td>Rs 5,800<\/td><td>High-margin specialty<\/td><\/tr><tr><td>Kotak Inst.<\/td><td>Buy<\/td><td>Rs 5,200<\/td><td>CDMO optionality<\/td><\/tr><\/tbody><\/table><\/figure><p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Paushak&#8217;s live price and receive real-time Q4 result alerts.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Paushak Q4 FY26 results will demonstrate the sustained power of its phosgene chemistry moat. At Rs 4,200, the stock is 38% below its 52-week high, with the market pricing in some execution uncertainty. Revenue toward Rs 95 Cr with PAT above Rs 22 Cr would confirm the business is on track. Any CDMO contract announcement with a global pharma company would be the most powerful potential catalyst. Consult a SEBI-registered advisor before investing.<\/p><p>This content is published by Univest, a SEBI-registered research and advisory platform. All analyst estimates and price targets cited are from publicly available broker notes. Past performance is not indicative of future results. Investors should conduct independent due diligence before making any investment decisions.<\/p><p>For more Q4 FY26 previews visit <a href=\"https:\/\/univest.in\/blogs\">Univest Blogs<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_Paushak_Q4_results_2026_date\"><\/span><strong>What is the Paushak Q4 results 2026 date?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Paushak Q4 FY26 results are scheduled for May 2026 (Expected). The board will meet to approve audited financial statements for the quarter ended March 31, 2026.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_Paushak_Q4_FY26_PAT_estimate\"><\/span><strong>What is the Paushak Q4 FY26 PAT estimate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Analysts estimate Paushak Q4 FY26 PAT in the range of Rs 18\u201326 Cr, on revenue of Rs 88\u2013102 Cr and margin of EBITDA 25\u201332%. Actual results may differ from these estimates.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_Paushaks_share_price_ahead_of_Q4_results\"><\/span><strong>What is Paushak&#8217;s share price ahead of Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Paushak shares are trading at approximately Rs 4,200 as of early April 2026. The 52-week high is Rs 6,800 and 52-week low is Rs 3,500. The one-year return is -32% and market cap stands at Rs 1,850 Cr.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Will_Paushak_declare_a_dividend_in_Q4_2026\"><\/span><strong>Will Paushak declare a dividend in Q4 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Paushak is expected to consider Rs 25\u201340 per share at the Q4 FY26 board meeting on May 2026 (Expected). The dividend decision reflects management&#8217;s confidence in FY26 free cash flow generation.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Which_analysts_have_a_Buy_rating_on_Paushak\"><\/span><strong>Which analysts have a Buy rating on Paushak?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>MOFSL (target Rs 5,500), YES Securities (target Rs 5,800), Kotak Inst. (target Rs 5,200) ahead of Q4 FY26 results.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_were_Paushak_Q3_FY26_results\"><\/span><strong>What were Paushak Q3 FY26 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>In Q3 FY26, Paushak reported revenue of Rs 78 Cr and PAT of Rs 15 Cr with margins at EBITDA 27.5%. These provided the base for Q4 FY26 analyst estimates.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"When_do_Infosys_and_TCS_announce_Q4_results_2026\"><\/span><strong>When do Infosys and TCS announce Q4 results 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>TCS announced Q4 FY26 results on April 9, 2026 \u2014 full preview at <a href=\"https:\/\/univest.in\/blogs\/tcs-q4-results-2026-date-preview\">TCS Q4 Results 2026<\/a>. <a href=\"https:\/\/univest.in\/blogs\/infosys-q4-results-2026-date-preview\">Infosys<\/a> announced results on April 23, 2026.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Is_Paushak_a_good_investment_ahead_of_Q4_results\"><\/span><strong>Is Paushak a good investment ahead of Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Paushak at Rs 4,200 offers a risk-reward contingent on Q4 execution and FY27 guidance. Investors should review analyst estimates, monitor the results announcement, and consult a SEBI-registered advisor before making investment decisions.<\/p><p>Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE\/BSE filings and company investor relations pages. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/natural-capsules-q4-results-2026\">Natural Capsules Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/national-fertilizers-q4-results-2026\">National Fertilizers Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/national-aluminium-company-q4-results-2026\">National Aluminium Company Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/nath-bio-genes-india-q4-results-2026\">Nath Bio-Genes (India) Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/narmada-agrobase-q4-results-2026\">Narmada Agrobase Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Paushak (NSE: PAUSHAK) is preparing to announce its Q4 FY26 financial results for the quarter ended March 31, 2026. With Paushak trading at Rs 4,200 \u2014 against a 52-week high of Rs 6,800 and a 1-year return of -32% \u2014 the Q4 FY26 results will be a pivotal event for investors tracking the Specialty Chemicals<\/p>\n","protected":false},"author":28,"featured_media":73822,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802,3858],"class_list":["post-73815","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news","tag-q4-results"],"metadata":{"_edit_lock":["1776663817:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"amazonS3_cache":["a:6:{s:63:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/image-1135.jpeg\";a:2:{s:2:\"id\";i:73818;s:11:\"source_type\";s:13:\"media-library\";}s:95:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20110849\/image-1135.jpeg\";a:2:{s:2:\"id\";i:73818;s:11:\"source_type\";s:13:\"media-library\";}s:138:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/Paushak-Q4-FY26-Analyst-Estimates-at-a-Glance-Source-MOFSL-YES-Securities-JM-Financial.jpg\";a:2:{s:2:\"id\";i:73820;s:11:\"source_type\";s:13:\"media-library\";}s:147:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/Paushak-Q4-FY26-Analyst-Estimates-at-a-Glance-Source-MOFSL-YES-Securities-JM-Financial-1024x536.jpg\";a:2:{s:2:\"id\";i:73820;s:11:\"source_type\";s:13:\"media-library\";}s:170:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20111020\/Paushak-Q4-FY26-Analyst-Estimates-at-a-Glance-Source-MOFSL-YES-Securities-JM-Financial.jpg\";a:2:{s:2:\"id\";i:73820;s:11:\"source_type\";s:13:\"media-library\";}s:179:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20111020\/Paushak-Q4-FY26-Analyst-Estimates-at-a-Glance-Source-MOFSL-YES-Securities-JM-Financial-1024x536.jpg\";a:2:{s:2:\"id\";i:73820;s:11:\"source_type\";s:13:\"media-library\";}}"],"rank_math_primary_category":["842"],"rank_math_seo_score":["81"],"rank_math_description":["Paushak Q4 results expected May 2026. Revenue estimate Rs 88\u2013102 Cr, PAT Rs 18\u201326 Cr. Phosgene chemistry moat and pharma intermediate preview with analyst targets."],"rank_math_title":["Paushak Q4 Results 2026: Date, Revenue and Phosgene Chemistry Estimates"],"rank_math_focus_keyword":["Paushak Q4 Results"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["73822"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["8480"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20111208\/Paushak-Q4-Results-2026.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/73815","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=73815"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/73815\/revisions"}],"predecessor-version":[{"id":73825,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/73815\/revisions\/73825"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/73822"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=73815"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=73815"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=73815"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}